% | $
Quotes you view appear here for quick access.

MannKind Corp. Message Board

mnholdem 18 posts  |  Last Activity: Jun 23, 2016 9:27 AM Member since: Mar 19, 2014
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • mnholdem mnholdem Jun 23, 2016 9:27 AM Flag


    "Building on results of this trial and those of six other smaller trials of STII therapy, a meta-analysis involving 839 participants (including 251 patients randomized to STII therapy in the above study was performed and further underscored the robustness of the evidence supporting STII therapy. In that analysis, 46% of patients remained in drug-free remission after 12 months.

    "All but one study showed an improvement in beta-cell function, as assessed by homeostatic model assessment [HOMA]-B, and all but one study showed a decrease in insulin resistance, as assessed by HOMA-IR.

    "In the pooled data, the proportion of patients in drug-free remission was:

    66.2% [292/441] at 3 months,
    58.9% [222/377] at 6 months,
    46.3% [229/495] at 12 months, and
    42.1% [53/126] at 24 months.

    "These rates of remission are far greater than those that can be achieved with any other currently available medical therapy for diabetes."

    NOTE: STII stands for Short-Term Intensive Insulin therapy

  • mnholdem mnholdem Jun 23, 2016 9:22 AM Flag

    Short-term intensive insulin therapy at diagnosis in type 2 diabetes: plan for filling the gaps

    Sentiment: Strong Buy

  • mnholdem mnholdem Jun 23, 2016 9:20 AM Flag

    Clinical Evidence for the Earlier Initiation of Insulin Therapy in Type 2 Diabetes

    Sentiment: Strong Buy

  • Reply to

    ADA policy on embargo

    by alpha228 Jun 3, 2016 4:49 PM
    mnholdem mnholdem Jun 3, 2016 10:30 PM Flag

    That must be why each abstract has a Share Page function. The purpose of the embargo is to prevent publication of the abstracts in any media outlets. The rest of you can go ahead and Share Page by forwarding the abstracts with your endo and ask him/her to take a few days of great food, entertainment and the 2016 ADA in New Orleans. Tell 'em that they deserve a few days off...and be sure to stop by the Afrezza display at the MannKind booth. :-)

    Sentiment: Strong Buy

  • mnholdem mnholdem Jun 3, 2016 10:17 PM Flag

    Your timelines are crossed but, yes, it's the same Joe. Very cool guy to have on board. I guess we'll all have to wait to see where former head of Sanofi's Global Diabetes Division Pascale Witz ends up. She would make a world-class CEO but her non-compete clause would likely forbid it for a couple more years.

  • Reply to

    Abstracts are up!

    by saxcmann Jun 3, 2016 5:18 PM
    mnholdem mnholdem Jun 3, 2016 9:42 PM Flag

    Each abstract has a Share Page feature, so you can send these to your endocrinologists. However, you cannot publish the abstracts or you may face sanctions by the ADA. So, share away!

    Sentiment: Strong Buy

  • mnholdem mnholdem Jun 2, 2016 10:31 PM Flag

    Setting short-term (ie TA charts) aside, the only events that will signal a "Buy" to me will be those events that indicate a significant increase in Afrezza sales will be the result. Frequency of posts (+ or -) is merely noise. These pros have a job to do, which is simply to distract investors from seeing the future value of Afrezza and Technosphere.

    Ignore them. Do your own work and conduct your own research. Then you will see the Buy signals ahead of most of Wall Street, who are content to wait until they see the actual increases in domestic sales of Afrezza. Frankly, waiting until you have sales confirmation is not a bad entry point either.

    Sentiment: Buy

  • Reply to

    Do bricks fall up?

    by chevyman317 May 26, 2016 3:15 PM
    mnholdem mnholdem May 27, 2016 10:12 AM Flag

    Bob doesn't have a clue. My PLM average is $0.7625 since buying the maximum allowable share of the $0.65 secondary offering for shareholders a few years back. Bob had lost his shirt by then, so he doesn't consider it important... there are other PLM investors I communicate with who are also green. Bob simply cannot believe that there are investors who might be smarter / more experienced than he thinks he is.

    Q: Why would anyone seriously consider investment advice from a brain-damaged loser like bobtrammel? A: They wouldn't.

    Sentiment: Hold

  • Reply to

    Now at $.79 cents and People you...

    by bobtramell May 24, 2016 12:43 PM
    mnholdem mnholdem May 27, 2016 10:01 AM Flag

    "Collectively, the brain power here on this site, less yours truly, Me, is that of a knat." - today's quote from a Gnat's #$%$ who cannot even spell gnat correctly.

    Not to worry. Eventually, bobtrammel will delete this thread.

  • Settlement date: Feb 12, 2016
    Short interest: 130,253,946

    Settlement date: April 29, 2016 (Disseminated: May 10, 2016)
    Short interest: 105,711,214

    That's a nearly 20% drop in short interest. So even though FUDsters are posting more frequently over the past few months, 1 out of 5 traders who shorted MNKD have bailed out during the same timeframe. You would think that after Sanofi terminated the License & Collaboration agreement that short interest would have skyrocketed, but the opposite is happening. Why?

    Are traders thinking the risks are getting too high to continue shorting MNKD? Is it only weak-kneed shorts who are bailing out of MNKD? Or have the smartest hedge fund managers decided to lock in their profits?

    Sentiment: Buy

  • mnholdem mnholdem May 1, 2016 7:43 PM Flag

    "Did you catch the last two lines?" Do you mean those lines where you added your own [interpretations]… and why would you even quote a site like Diapedia and attempt to use the quote, to which you had to add your own incorrect [interpretations], in order to contradict the very company that manufactures lispro? Are you kidding me?

    Many of these quotes are from years ago, before Afrezza came to market. The regular human insulins referred to were brands like Novalin an Humalin, both of which are injected hexamer insulins like lispro. Lispro's chemical chain has been modified to help speed up its dissolution into a monomer insulin that the body can use, but it's not as rapid as Afrezza, a human insulin delivered via pulmonary administration into the bloodstream as a monomer in an inhalable dry formulation.

    So this latest attempt of yours to present your [evidence] as "facts" is another simply pathetic effort to deceive people.

    Sentiment: Strong Buy

  • mnholdem mnholdem Apr 27, 2016 7:35 AM Flag

    I hate (not really) to inform you, fragslap:

    Tuesday, April 26, 2016 - Plaintiff's Motion for Consolidation - DENIED

    MINUTES (IN CHAMBERS) Order Re: Vladimir Rivkin's Motion for Consolidation, Appointment of Lead Plaintiff, and Approval of Selection of Counsel (DE 8) Masoud Paydar's Motion for Consolidation, Appointment of Lead Plaintiff, and Approval of Selection of Counsel (DE 14) Proposed Joint Stipulation Regarding Appointment of Lead Plaintiffs and Approval of Selection of Counsel (DE 16) by Judge R. Gary Klausner: Plaintiffs' Motion for Consolidation, Appointment, and Approval and Joint Stipulation are DENIED without prejudice. See Civil Minutes For Specifics. (bp)


    However, the case against MannKind has not been dismissed...yet. When that does happen, management will likely issue a press release, so I'm not going to waste a lot of time checking the dockets. Especially when I can be digging at who MannKind's newest partners are for the ex-U.S. sales & distribution of Afrezza.

    Good fortune all. :-)

    Sentiment: Strong Buy

  • mnholdem mnholdem Apr 25, 2016 3:24 PM Flag

    No, it doesn't say anything about dismissal in this notice related a motion by one of the firms, but it does state, "The court will issue a ruling after full consideration of properly submitted pleadings." Those submittals will include the submittals required by the court (on its own motion rather than any motion by the various firms) to show cause why this case shouldn't be dismissed.

    So the calendar is scheduled for the judge to make a ruling today (April 25) on the motion of Vladimir Rivkin to consolidate [relate actions & and cases]. I can read. But today's decision will likely result in the judge denying the motion to consolidate, based on his decision that the various firms have not submitted sufficient cause for the case(s) to not be dismissed.

    Picking only those document that supports your argument and ignoring the rest, especially the one document that was based on a motion by the court itself, is typical of bashers, who make a living on half-truths and innuendos.

    I think this case will be dismissed. If it's not, who cares? The insurance will cover it. Why are you making such a big deal over this issue? I'll tell everyone why. It's because my original post challenged your blatant LIE that MannKind cannot afford to lose this lawsuit when you know full well that they won't have to pay a penny even if they lose...unless you count the insurance premium.

    Sentiment: Strong Buy

  • mnholdem mnholdem Apr 25, 2016 12:58 PM Flag

    If you're going to ever gain any credibility, you need to post in a way that nobody can make you eat your own words and look like a fool. Here is the post you are referring to:

    mnholdem • Apr 22, 2016 5:23 PM Remove

    4 users liked this posts users disliked this posts 1
    April 5, 2016: "MINUTE ORDER IN CHAMBERS Order to Show Cause re Dismissal for Lack of Prosecution by Judge R. Gary Klausner: The court, on its own motion, orders plaintiff(s) to show cause in writing on or before April 21, 2016 why this action should not be dismissed for lack of prosecution."

    Judge Klauser likely has read the Disclaimer of Forward-Looking Statements which has accompanied every conference call and next week he will dismiss the court case. Less

    Sentiment: Strong Buy


    I notice that you selectively omitted my quote of the judge's April 5 order for all plaintiff's to show cause why this action should not be dismissed. Justices rarely issue these "show cause" orders unless they are considering dismissal. That he wanted plaintiffs replies submitted to him in writing by April 21 indicates that he will announce his decision to either consolidate or to dismiss at today's hearing.

    If he chooses not to dismiss, it really doesn't matter to the day-to-day operations of Mannkind Corporation, since the company has an insurance policy to protect itself against lawsuits.


    Good Fortune All

    Sentiment: Strong Buy

  • mnholdem mnholdem Apr 22, 2016 5:23 PM Flag

    April 5, 2016: "MINUTE ORDER IN CHAMBERS Order to Show Cause re Dismissal for Lack of Prosecution by Judge R. Gary Klausner: The court, on its own motion, orders plaintiff(s) to show cause in writing on or before April 21, 2016 why this action should not be dismissed for lack of prosecution."

    Judge Klauser likely has read the Disclaimer of Forward-Looking Statements which has accompanied every conference call and next week he will dismiss the court case.

    Sentiment: Strong Buy

  • Excerpts from today's press that cover the meeting in Aurora last night:

    About 400 people attended a public meeting on the Iron Range Tuesday night on the proposed PolyMet mine, an event the company's CEO called a major milestone in its more than decade-long effort to open the state's first copper-nickel mine.

    The state's Department of Natural Resources and Pollution Control Agency hosted the event at Mesabi East High School in Aurora, which was crowded largely by PolyMet supporters sporting blue "We Support Mining" stickers.

    The public meeting paves the way for PolyMet to apply for the more than 20 federal, state and local permits it will need to build the mine near the small towns of Babbitt and Hoyt Lakes in far northeast Minnesota.

    "We've been working very hard to get to this point for a number of years," said PolyMet CEO Jon Cherry. He said the company's permit applications are already "fairly well developed," and said he anticipated those would be filed "in a matter of months," likely by the end of June.


    PolyMet has proposed a host of features at the mine and processing plant to capture and treat water pollution. Because the DNR in the environmental review process already said the project as proposed will meet state water standards, PolyMet CEO Jon Cherry said he doesn't foresee any hurdles in the permitting process.

    "I'd be surprised if we came up with anything that would be a fatal flaw at this point," he said. He said the permit applications will provide more detail to back up the environmental review.

    The DNR has pledged to post that application on its website as soon as it's received. Assistant Commissioner Barb Naramore said she'll have a better idea how long it will take the agency to decide on permit applications once the agency receives them. But she said it will be a matter of months, not weeks.

    Sentiment: Buy

  • Press release - The DNR and the Minnesota Pollution Control Agency launched a PolyMet/NorthMet project information web page to keep citizens informed on the upcoming permits needed for the project to move forward.

    The new web page can be found at http://polymetDOTmnDOTgov

    Sentiment: Buy

  • mnholdem mnholdem Apr 17, 2016 1:13 PM Flag

    Short-acting insulin analogs are designed to overcome the limitations of conventional regular human insulin. Insulin lispro (Humalog), formerly called LYSPRO from the chemical nomenclature [LYS(B28), PRO(B29)], is the first commercially available insulin analog. Compared with regular human insulin, this insulin analog offers the advantages of faster subcutaneous absorption, an earlier and greater insulin peak, and a shorter duration of action.11,12

    The benefits achieved by insulin lispro are related to a sequence switch of two beta-chain amino acids. Human insulin, a protein hormone composed of two polypeptide chains, has a linked A chain and B chain. In insulin lispro, reversal of the proline at B-28 and the lysine at B-29 results in more rapid dissolution of this insulin to a dimer and then to a monomer that is absorbed more rapidly after subcutaneous injection6 (Figure 1).13


    The information above is from a link provided by Eli-Lilly, makers of the first Rapid Acting Analog (RAA) insulin known as Lispro.

    What fragslap posted is a falsehood. As you can read, Lispro is not a monomer insulin in its liquid state. It's certainly faster than Humalin and Novalin at dissolution to a dimer and then to a monomer, but must still go through the process of dissolution.

    Afrezza, on the other hand, is the world's first insulin that is immediately delivered as a monomer insulin, suspended in its monomer form through a patented dry formulation process.mThe fact that Afrezza is inhaled is not its most important benefit. If a monomer insulin could be stored in a liquid without deteriorating, it would have been on the market years ago.

    Good fortune all.

    Sentiment: Strong Buy

1.16-0.02(-1.69%)Jun 30 4:00 PMEDT